Nitin Jain: Our trial of ponatinib VEN + mini-CVD for R/R T-ALL is now open

Nitin Jain, the Director of the Leukemia CAR-T Program at the MD Anderson Cancer Center, shared on X/Twitter:

“Excited to share that our trial of ponatinib (as LCK inhibitor) + VEN + mini-CVD for R/R T-ALL is now open. Joint collaboration with MDACC and St Jude Hospital.
Jun Yang and Jiyang Yu showed 40% T-ALL overexpress LCK and sensitive to ponatinib/dasatinib (Notably, none had ABL fusion).
This trial is supported by The Leukemia and Lymphoma Society LLS TRP grant. A truly unmet medical need. Please DM or email me for any potential patients.”

Source: Nitin Jain/X